Cannabinoids for the treatment of mental disorders - Author's reply

Affiliations

¹ National Drug and Alcohol Research Centre, University of New South Wales, Sydney NSW 2052, Australia.
² Centre for Youth Substance Abuse Research, University of Queensland, Brisbane QLD, Australia; National Addiction Centre, Kings College London, London, UK.
³ National Drug and Alcohol Research Centre, University of New South Wales, Sydney NSW 2052, Australia. Electronic address: l.degenhardt@unsw.edu.au.

Comment

Nicola Black et al. Lancet Psychiatry. 2020 Feb.

. 2020 Feb;7(2):127-128.

doi: 10.1016/S2215-0366(19)30526-7.

¹ National Drug and Alcohol Research Centre, University of New South Wales, Sydney NSW 2052, Australia.
² Centre for Youth Substance Abuse Research, University of Queensland, Brisbane QLD, Australia; National Addiction Centre, Kings College London, London, UK.
³ National Drug and Alcohol Research Centre, University of New South Wales, Sydney NSW 2052, Australia. Electronic address: l.degenhardt@unsw.edu.au.

No abstract available

Comment on

Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.
Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L. Black N, et al. Lancet Psychiatry. 2019 Dec;6(12):995-1010. doi: 10.1016/S2215-0366(19)30401-8. Epub 2019 Oct 28. Lancet Psychiatry. 2019. PMID: 31672337 Free PMC article.
Cannabinoids for the treatment of mental disorders.
Mauer S. Mauer S. Lancet Psychiatry. 2020 Feb;7(2):125. doi: 10.1016/S2215-0366(19)30509-7. Lancet Psychiatry. 2020. PMID: 31981532 No abstract available.
Cannabinoids for the treatment of mental disorders.
Crippa JA, de Lima Osório F, Hallak J, Guimarães FS, Zuardi AW. Crippa JA, et al. Lancet Psychiatry. 2020 Feb;7(2):125-126. doi: 10.1016/S2215-0366(19)30516-4. Lancet Psychiatry. 2020. PMID: 31981533 No abstract available.
Cannabinoids for the treatment of mental disorders.
Feingold D, Lev-Ran S. Feingold D, et al. Lancet Psychiatry. 2020 Feb;7(2):126-127. doi: 10.1016/S2215-0366(19)30523-1. Lancet Psychiatry. 2020. PMID: 31981534 No abstract available.